We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Large Outcomes Study Explores QOL After Diagnosis

Feb 1, 1999
Volume: 
8
  • Prostate Cancer

CHICAGO—In 1994, the National Cancer Institute began a
large-scale, longitudinal investigation of health-related quality of
life outcomes in men diagnosed with prostate cancer. Arnold Potosky,
PhD, updated the trial’s progress at a quality of life and
outcomes symposium sponsored by Northwestern University and Evanston
Northwestern Healthcare.

The project team is currently analyzing changes in quality of life
after a prostate cancer diagnosis in the study population, said Dr.
Potosky, senior investigator in the National Cancer Institute’s
Division of Cancer Control and Population Science. Ultimately, he
expects the findings will be incorporated into clinical practice to
assist patients and physicians in making decisions about prostate
cancer treatment.

The project, known as the Prostate Cancer Outcomes Study, is being
conducted by the NCI’s Surveillance, Epidemiology, and End
Results (SEER) program in collaboration with six SEER cancer
registries.

The study is designed to determine the prevalence of complications
across a large population of men with prostate cancer and provide
generalizable results concerning prostate cancer practice patterns.
It is measuring variations in care, specific aspects of quality of
life, and the influence of comorbid conditions in men with
histologically confirmed invasive cancer of the prostate.

“The objective is to find men soon after diagnosis and follow
them over the long term,” Dr. Potosky said. To meet this goal,
the study used a rapid case ascertainment system that identified men
within 6 to 8 weeks of their diagnosis and mailed them a survey that
asked about their bowel and bladder symptoms and sexual function 6,
12, and 24 months after their diagnosis.

The study also obtains detailed information about the clinical
characteristics of the disease and the use of various types of
treatment through medical record abstracts from physicians and hospitals.

Since the study began, about 3,500 men out of a total identified
sample of 5,600 men have completed 6- or 12-month surveys. The racial
and ethnic breakdown is approximately 500 non-Hispanic black, 500
Hispanic, and 2,500 non-Hispanic white.

The cohort is drawn from six SEER areas (Los Angeles, Utah, Seattle,
New Mexico, Atlanta, and Connecticut), and the study population is
representative of the population of men with prostate cancer in the
SEER areas. Dr. Potosky noted that “this is not to say that SEER
areas are representative of the country as a whole.”

The NCI plans to conduct ongoing analyses of the data collected by
the study and to publish a newsletter for men who participate in the
study to keep them informed of its progress. The Institute also seeks
“to get the word out about what we’re doing and get
feedback,” Dr. Potosky said.

Related Articles

  • No Improved Outcomes in Prostate Cancer With ADT Plus Mitoxantrone/Prednisone
  • No Benefit in Outcomes With Higher Resource Use in Metastatic Prostate Cancer
  • Proton RT for Prostate Cancer Has Reduced Toxicity, Higher Cost vs Other RT Options
  • ‘Screening Smarter’ for Prostate Cancer
  • Enzalutamide Granted Priority Review for Expanded Use in Prostate Cancer

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.